Wilmington, MA April 11, 2018—Micro Medical Solutions (MMS) is positioning itself for growth and product commercialization with the recent addition of two new employees to its organization: Amanda Panos as Vice President, Clinical Affairs, and Sarrah Val as Director of Clinical Affairs.

Ms. Panos brings 20 years of experience in the medical device industry, where her primary focus has been research of vascular disease management. She has implemented pre-clinical, first-in-man, feasibility, pivotal and post-market clinical studies in the U.S. and abroad to support market filings—experience she will draw on in her capacity at MMS.

“I’m excited to have Amanda lead our clinical efforts, as this is the foundation for building the value of MMS,” says Gregory Sullivan, CEO of MMS. “Her global experience in the execution of clinical trials will play a key role in our success moving forward. She is an outstanding addition to our leadership team,” he says.

MMS is also pleased to welcome Sarrah Val as Director of Clinical Affairs, a role that will draw on her background in clinical trial protocol development and execution.

“Sarrah is an exceptional addition to our clinical team,” Panos says. “Her proven track record of clinical achievement in the below-the-knee space is invaluable. She will be instrumental in moving MMS through critical clinical timelines. I’m honored to have her on my team,” she says.

MMS has invested significant resources in moving its clinical objectives forward, with continued focus on the company’s mission to reduce preventable amputations by improving outcomes for patients with peripheral artery disease (PAD) and critical limb ischemia (CLI). One key result is FDA approval of a feasibility study for MicroStent, which MMS is confident will lead to a pivotal IDE study, another step toward its ultimate goal of device approval.

CONTACT: Peg Thornton, Director of Corporate and Market Development, Micro Medical Solutions 732-616-9123